{
    "Patient": {
        "Name": "Heather Smith",
        "DOB": "1995-05-30",
        "Sex": "Male",
        "Caseno": "9572",
        "Diagnosis": "Small cell lung cancer",
        "Physician": "Dr. Lisa Sullivan"
    },
    "specimen information": {
        "primary_tumor_site": "Lung",
        "specimen_site": "Mediastinal lymph nodes",
        "specimen_ID": "2885",
        "CollectedDate": "2023-05-12",
        "ReceivedDate": "2023-05-14",
        "Pathological Diagnosis": "Left breast, central, 12:00, suspicious mass, 12-gauge core needle biopsy: Infiltrating moderately-differentiated mammary carcinoma, grade 2, Nottingham score 6 (architectural grade 3, nuclear grade 2, mitotic figures 1).",
        "Dissection Information": "Molecular testing of this specimen was performed after harvesting of targeted tissues with an approved manual microdissection technique. Candidate slides were examined under a microscope and areas containing tumor cells (and separately normal cells, when necessary for testing) were circled. A laboratory technician harvested targeted tissues for extraction from the marked areas using a dissection microscope."
    },
    "Results with Therapy association": [
        {
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 3+, 100%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine",
                "therapy",
                "everolimus"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 2+, 95%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine therapy"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "TMB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "6 m/Mb Low",
            "Therapy association": [
                "BENEFIT",
                "pembrolizumab"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "ERBB2",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative | 0",
            "Therapy association": [
                "LACK OF BENEFT",
                "trastuzumab",
                "ado-trastuzumab emtansine",
                "pertuzumab",
                "fam-trastuzumab deruxtecan-nxki",
                "lapatinib",
                "neratinib",
                "tucatinib"
            ],
            "Biomarker_level": "level 1"
        }
    ],
    "Relevant Biomarkers": [
        {
            "BioMarker": "PD-L1(SP142)",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 1+, 31%"
        },
        {
            "BioMarker": "IKZF1",
            "Method": "Seq",
            "Analyte": "DNA-Tumor",
            "Result": "Stable"
        },
        {
            "BioMarker": "BLM",
            "Method": "Seq",
            "Analyte": "DNA-Tumor",
            "Result": "Fusion not detected"
        },
        {
            "BioMarker": "Mismatch repair status",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Positive| 1+, 78%"
        }
    ],
    "Genomic Signatures": [
        {
            "BioMarker": "Microsatellite instability",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "Low"
        },
        {
            "BioMarker": "Tumor mutational burden",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "6 mutations/Mb Low"
        },
        {
            "BioMarker": "Genomic loss of heterozygosity (LOH)",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High - 36% of tested genomic segments exhibit LOH"
        }
    ],
    "Genes Tested with Pathogenic Alterations": [
        {
            "Gene": "ARID2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Pathogenic",
            "Protien Alteration": "p.K385L",
            "Exon": 3,
            "DNA Alteration": "c.1153_1154delinsTT",
            "Allele Frequency %": "14.27"
        },
        {
            "Gene": "H3.3",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Pathogenic",
            "Protien Alteration": "p.G1386D",
            "Exon": 19,
            "DNA Alteration": "3",
            "Allele Frequency %": "4.16"
        },
        {
            "Gene": "BRAF",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.R132G",
            "Exon": 12,
            "DNA Alteration": "c.394_395delinsTC",
            "Allele Frequency %": "28.79"
        }
    ],
    "Gene variants of unknown significance": [
        {
            "Gene": "KRAS",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.H1038R",
            "Exon": 7,
            "DNA Alteration": "c.3113A>G",
            "Allele Frequency %": "3.49"
        },
        {
            "Gene": "STAG2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.R683G",
            "Exon": 18,
            "DNA Alteration": "c.1849G>T",
            "Allele Frequency %": "20.84"
        },
        {
            "Gene": "IKZF1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.R256fs*64",
            "Exon": 3,
            "DNA Alteration": "c.766_776del11",
            "Allele Frequency %": "7.01"
        }
    ],
    "Immunohistochemistry results": [
        {
            "Biomarker": "AR",
            "Result": "Positive| 3+, 58%"
        },
        {
            "Biomarker": "ER",
            "Result": "Positive| 3+, 85%"
        },
        {
            "Biomarker": "PTEN",
            "Result": "Positive| 3+, 68%"
        },
        {
            "Biomarker": "MLH1",
            "Result": "Negative| 1+, 72%"
        }
    ],
    "Genes Tested with indeterminate results": [
        "CHD6",
        "PTCH1",
        "KLF1",
        "SRSF2",
        "HRAS",
        "TOP2A"
    ],
    "Chemotherapy clinical trials": [
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti inflammatory agents",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "aspirin"
            ]
        }
    ],
    "Targeted therapy clinical trials": [
        {
            "Drug class": "Akt inhibitors",
            "Biomarker": "ARID1A",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "MK-2206",
                "ipataserib"
            ]
        },
        {
            "Drug class": "immunomodulatory agents",
            "Biomarker": "TMB",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "avelumab",
                "atezolizumab",
                "durvalumab",
                "ipilimumab",
                "nivolumab",
                "pembrolizumab"
            ]
        },
        {
            "Drug class": "PARP inhibitors",
            "Biomarker": "NBN",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "BGB-290",
                "BMN-673",
                "olaparib",
                "rucaparib",
                "talazoparib"
            ]
        },
        {
            "Drug class": "Akt/mTor inhibitors",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "BYL719",
                "MK-2206",
                "ipataserib",
                "everolimus",
                "temsirolimus"
            ]
        }
    ]
}